DXCM Stock Gains on the Launch of Proprietary Generative AI Platform

Zacks2024-12-18

DexCom Inc. DXCM recently announced the launch of a proprietary Generative AI (GenAI) platform, making Dexcom the first Continuous Glucose Monitoring (CGM) manufacturer to integrate GenAI into glucose...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492136130?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cQh8dmZYcaVCEef9kDcJiQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e1e661692a97423f623854b9b5e54b7d","is_english":true,"pubTime":"2024-12-18 23:34","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492136130","market":"us","top_or_hot":-1,"title":"DXCM Stock Gains on the Launch of Proprietary Generative AI Platform","media":"Zacks","content":"<div>\n<p>DexCom Inc. DXCM recently announced the launch of a proprietary Generative AI (GenAI) platform, making Dexcom the first Continuous Glucose Monitoring (CGM) manufacturer to integrate GenAI into glucose...</p>\n\n<a href=\"https://finance.yahoo.com/news/dxcm-stock-gains-launch-proprietary-153400993.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DXCM Stock Gains on the Launch of Proprietary Generative AI Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDXCM Stock Gains on the Launch of Proprietary Generative AI Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 23:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/dxcm-stock-gains-launch-proprietary-153400993.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DexCom Inc. DXCM recently announced the launch of a proprietary Generative AI (GenAI) platform, making Dexcom the first Continuous Glucose Monitoring (CGM) manufacturer to integrate GenAI into glucose...</p>\n\n<a href=\"https://finance.yahoo.com/news/dxcm-stock-gains-launch-proprietary-153400993.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0205193047.USD","symbol_name":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/dxcm-stock-gains-launch-proprietary-153400993.html","article_id":"2492136130","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cQh8dmZYcaVCEef9kDcJiQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e1e661692a97423f623854b9b5e54b7d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492136130","pubTimestamp":1734536040,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"DexCom Inc. DXCM recently announced the launch of a proprietary Generative AI  platform, making Dexcom the first Continuous Glucose Monitoring  manufacturer to integrate GenAI into glucose biosensing technology.In addition to offering practical insights to support the improvement of metabolic health, the new Dexcom GenAI platform is likely to examine trends in individual health data to uncover a clear correlation between lifestyle decisions and blood glucose levels. Dexcom leveraged Google Cloud’s cutting-edge Vertex AI platform and Gemini models as the foundation to build its proprietary GenAI platform.Stelo, the first over-the-counter glucose biosensor clearedby the FDA in the United States, is the first Dexcom product to use GenAI-enabled technology to produce weekly insights. This week, consumers began to reap the benefits of Stelo's Weekly Insights feature upgrade.GenAI-powered messaging complements Stelo's current Weekly Insights by providing users with additional contextualized ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4082":"医疗保健设备","AXGN":"AxoGen Inc.","LU2764262908.HKD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (HKD) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","BK4588":"碎股","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU2764263039.SGD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (SGDHDG) ACC","MASI":"麦斯莫医疗","LU2764263203.CNY":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (CNYHDG) ACC","BK4551":"寇图资本持仓","DXCM":"德康医疗","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","ARAY":"精确射线","BK4504":"桥水持仓","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc"},"translate_title":"推出专有生成式人工智能平台，DXCM股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXGN":1,"MASI":1,"DXCM":1,"ARAY":1},"content_text":"DexCom Inc. DXCM recently announced the launch of a proprietary Generative AI (GenAI) platform, making Dexcom the first Continuous Glucose Monitoring (CGM) manufacturer to integrate GenAI into glucose biosensing technology.\nIn addition to offering practical insights to support the improvement of metabolic health, the new Dexcom GenAI platform is likely to examine trends in individual health data to uncover a clear correlation between lifestyle decisions and blood glucose levels. Dexcom leveraged Google Cloud’s cutting-edge Vertex AI platform and Gemini models as the foundation to build its proprietary GenAI platform.\nStelo, the first over-the-counter glucose biosensor cleared by the FDA in the United States, is the first Dexcom product to use GenAI-enabled technology to produce weekly insights. This week, consumers began to reap the benefits of Stelo's Weekly Insights feature upgrade.\nGenAI-powered messaging complements Stelo's current Weekly Insights by providing users with additional contextualized sleep, exercise, nutrition advice, recommendations, and education within the Stelo app. Dexcom's proprietary platform establishes a foundation for future GenAI advancements across its product portfolio, empowering millions of users to take control of their health.\nLikely Trend of DXCM Stock Following the News\nFollowing the announcement, shares of the company moved north 1.8% to $77.80 on yesterday’s closing. In the year-to-date period, DXCM shares have lost 37.3% against the industry’s rise of 5.4%. The S&P 500 has gained 28.3% in the same time frame.\nImage Source: Zacks Investment Research\nLikely Benefits of the Proprietary Gen AI Platform to DXCM\nDexcom can benefit greatly from incorporating Gen AI into glucose biosensing, especially in improving the accuracy and customization of diabetes treatment. The platform can evaluate enormous volumes of glucose data in real-time by utilizing cutting-edge artificial intelligence, spotting patterns and trends that were previously hard to spot.\nUsers can make well-informed decisions regarding their food, activity, and medicine thanks to the extremely accurate glucose readings and projections they receive. Furthermore, Gen AI can tailor alerts and suggestions according to each person's glucose sensitivity, improving blood sugar regulation and lowering the chance of problems.\nBetter accessibility and user experience are two other significant advantages of applying Gen AI to glucose biosensing. The platform facilitates successful collaboration between users, caregivers, and healthcare providers by distilling complex glucose data into easily comprehensible insights.\nAdditionally, it facilitates continuous learning, which allows the system to provide more intelligent and trustworthy advise over time by adjusting to each user's unique glucose patterns. Moreover, this technology can expedite Dexcom's product development, facilitating quicker innovation and the production of glucose monitoring devices that are more effective. Through the application of Gen AI, Dexcom is establishing a new benchmark in treating diabetes by providing consumers with more intelligent, quick, and user-friendly tools.\nDXCM’s Recent Product Updates & Partnership\nDexcom has been at the forefront of innovation in diabetes management, with several recent updates showcasing its commitment to improving glucose monitoring. In August 2024, Dexcom launched the Dexcom Stelo, an over-the-counter CGM specifically designed for individuals with Type 2 diabetes not requiring insulin and those managing prediabetes.\nStelo offers real-time glucose tracking via a smartphone app, eliminating the need for a prescription and making advanced glucose monitoring more accessible. Priced at $99 for a pack of two 15-day sensors, Stelo aims to bridge the gap in diabetes care for underserved populations, reflecting Dexcom’s focus on affordability and user convenience.\nIn addition to product launches, Dexcom continues to refine its existing offerings. A recent update to the Dexcom G6 app introduced an iOS widget, allowing users to view their glucose readings directly from their home screens without opening the app. This small yet impactful feature enhances convenience, ensuring critical health data is always within reach.\nDexcom’s focus on iterative improvements demonstrates its commitment to meeting user needs through continuous innovation. Collectively, these advancements position Dexcom as a leader in diabetes care, with a clear focus on accessibility, user engagement, and cutting-edge technology.\nIn November, Dexcom partnered with Oura, integrating its CGM devices with the Oura Smart Ring, a wearable health tracker. This collaboration enables users to monitor their glucose levels alongside other health metrics like sleep and activity, providing a holistic view of their well-being. The integration is expected to enhance the user experience by offering actionable insights into how lifestyle factors impact glucose levels, helping users make better-informed decisions about their health. This partnership reflects Dexcom’s push toward creating interconnected healthcare ecosystems that leverage wearable technology for comprehensive health management.\nFavorable Industry Prospects for DXCM\nPer a report by Grand View Research, the global generative AI in the healthcare market was valued at $1.28 billion in 2022 and is projected to witness a CAGR of 36.7% from 2023 to 2030, reaching approximately $14.77 billion by 2030.\nThis growth is driven by advancements in deep learning and natural language processing, increasing demand for personalized treatment, and rising healthcare data volumes.\nDXCM’s Zacks Rank & Stocks to Consider\nDXCM carries a Zacks Rank #3 (Hold) at present.\nSome better-ranked stocks in the broader medical space are Masimo MASI, Accuray ARAY and AxoGen AXGN.\nMasimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 11.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.\nMASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Its shares have risen 49.4% compared with the industry’s 6.7% growth year to date.\nAccuray, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 1200% for 2025. Its earnings missed estimates in three of the trailing four quarters and met in one, delivering an average negative surprise of 141.97%.\nARAY’s shares have lost 32.2% against the industry’s 6.7% growth year to date.\nAxoGen, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 252% for 2025. It delivered a trailing four-quarter average earnings surprise of 91.11%.\nAXGN’s shares have risen 111% year to date compared with the industry’s 6.7% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAccuray Incorporated (ARAY) : Free Stock Analysis Report\nMasimo Corporation (MASI) : Free Stock Analysis Report\nDexCom, Inc. (DXCM) : Free Stock Analysis Report\nAxoGen, Inc. (AXGN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492136130"}